Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

I-Mab looks to fill gap in NASDAQ listings by Chinese players

October 31, 2019 12:24 AM UTC
Updated on Oct 31, 2019 at 10:35 PM UTC

I-Mab Biopharma is hoping to become only the second innovative Chinese drug developer since Zai two years ago to go public on NASDAQ.

The Shanghai-based company has proposed to raise up to $100 million in an offering underwritten by Jefferies, CICC, China Renaissance and Huatai Securities...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

I-mab